{"id":41,"date":"2021-11-02T08:00:00","date_gmt":"2021-11-02T08:00:00","guid":{"rendered":"https:\/\/dalriadatx.com\/2022\/04\/27\/blog-post-title-3\/"},"modified":"2022-09-19T04:20:58","modified_gmt":"2022-09-19T04:20:58","slug":"dalriada-congratulates-client-dunad-therapeutics-on-billion-dollar-collaboration-with-novartis","status":"publish","type":"post","link":"https:\/\/dalriadatx.com\/post\/dalriada-congratulates-client-dunad-therapeutics-on-billion-dollar-collaboration-with-novartis\/","title":{"rendered":"Dalriada Congratulates Client Dunad Therapeutics on Billion Dollar Collaboration with Novartis"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"41\" class=\"elementor elementor-41\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-7009a1d elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"7009a1d\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3106626 jltma-glass-effect-no\" data-id=\"3106626\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3bbbc22 jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"3bbbc22\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.20.0 - 26-03-2024 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p>Dunad Therapeutics enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies<\/p>\n<ul>\n<li>Novartis to leverage Dunad\u2019s proprietary platform to generate novel oral covalent and protein degrading small molecule drugs across multiple target classes<\/li>\n<li>Novartis has exclusive option to license, develop and commercialize resulting candidates for up to four targets<\/li>\n<li>Dunad to receive $24 million in an upfront payment and equity investment, as well as research funding<\/li>\n<li>Dunad eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments<\/li>\n<\/ul>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-6bb045d elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"6bb045d\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1da37ed jltma-glass-effect-no\" data-id=\"1da37ed\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9a321fd jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"9a321fd\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p><strong>Cambridge, UK, November 2, 2021<\/strong> &#8211; Dunad Therapeutics (\u201cDunad\u201d), a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies, today announces that it has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs.<\/p>\n<p>Under the terms of the agreement, Dunad will apply its tunable and highly selective platform to generate novel covalent and targeted protein degrading small molecule drugs focusing on up to four drug targets agreed with Novartis. Dunad will also be responsible for program execution up to lead optimization. Novartis will contribute target and ligand knowledge as well as access to unique assays and models and will fully fund the research collaboration.<\/p>\n<p>Novartis has an exclusive option to develop and commercialize products resulting from the research programs directed against up to four drug targets. Upon exercise of this option, Novartis will assume responsibility for future development, manufacturing and global commercialization of the small molecule therapeutic products generated against the agreed targets\u200b.<\/p>\n<p>Dunad\u2019s unique platform uses mono-valent small molecules to induce selective degradation of disease-causing and often undruggable proteins via direct modification of the target. The Company\u2019s novel molecular approach is fully tunable to be selective and is underpinned by a target-class agnostic mechanism of action that is clearly differentiated from other targeted protein degradation technologies.<\/p>\n<p>Dunad\u2019s platform has the potential to generate orally bioavailable degrader therapeutics that significantly expand the frontiers of protein degradation targets. Under the terms of the agreement, Dunad will receive $24 million in an upfront payment and equity investment, as well as significant research funding. Dunad will also be eligible for milestone payments that could aggregate to up to $1.3 billion and royalties.<\/p>\n<p>Alongside the equity investment of Novartis, and the founding investor Epidarex Capital, BioGeneration Ventures (BGV) is joining Dunad as a new investor. Oskar Slotboom, General Partner at BGV, has joined Dunad\u2019s Board of Directors.<\/p>\n<p><strong>Prof. Patrick Gunning, Dunad\u2019s co-founder, acting Chief Executive Officer and Chief Scientific Officer commented:<\/strong> <em>\u201cWe are thrilled to have entered this collaboration with Novartis, which has already established a world leading position in the protein degradation space. This deal highlights the clear benefits our platform promises for the development of next-generation targeted protein degrader therapeutics. We are confident that with our approach of inducing degradation via direct modulation of target proteins with mono-valent small molecules, we can significantly expand the boundaries of targeted protein degraders as a therapeutic modality.\u201d <\/em><\/p>\n<p><strong>Dr. Diana Kraskouskaya, co-founder and Chief Operating Officer of Dunad, commented:<\/strong> <em>\u201cThis collaboration is an important milestone for Dunad. It allows us to rapidly expand the impact of our platform technology to additional target classes and therapeutic areas, beyond Dunad\u2019s own internal target pipeline. Our growing team is committed to advancing our internal pipeline and partnered programs directed against the most sought-after and previously intractable targets.\u201d <\/em><\/p>\n<p><strong>Dr. Elizabeth Roper, Partner at Epidarex Capital, Dunad\u2019s founding investor, and board director of Dunad, commented:<\/strong> <em>\u201cWe are delighted to see Dunad\u2019s growth continue with such a significant deal with Novartis. This collaboration provides validation of Dunad\u2019s differentiated protein degradation technology and explores the full potential of this new modality as a therapeutic approach. We are also excited to welcome BGV and Novartis as investors to the syndicate and look forward to our continued collaboration with the team.\u201d<\/em><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-927b5d7 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"927b5d7\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-28de0e1 jltma-glass-effect-no\" data-id=\"28de0e1\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1de2d54 jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"1de2d54\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<h2>About Dunad Therapeutics:<\/h2>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-faa4131 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"faa4131\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3030bd4 jltma-glass-effect-no\" data-id=\"3030bd4\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ecbc804 jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"ecbc804\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad\u2019s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.<\/p>\n<p>Dunad was founded in 2020 and is headquartered in Cambridge, UK with operations in both the UK and North America and is backed by founding investor Epidarex Capital as well as BioGeneration Ventures (BGV) and Novartis. For more information, please visit: <a href=\"https:\/\/www.dunad.co.uk\/\" target=\"_blank\" rel=\"noopener\">www.dunad.co.uk<\/a><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Dunad Therapeutics enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies<\/p>\n","protected":false},"author":2,"featured_media":847,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"post_folder":[],"_links":{"self":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts\/41"}],"collection":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/comments?post=41"}],"version-history":[{"count":0,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts\/41\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/media\/847"}],"wp:attachment":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/media?parent=41"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/categories?post=41"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/tags?post=41"},{"taxonomy":"post_folder","embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/post_folder?post=41"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}